

Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for bupropion, the scientific conclusions are as follows:

In view of available data on Brugada syndrome from spontaneous reports, including 2 cases with a positive de-challenge and plausible time to onset and in view of a plausible mechanism of action described in literature, the PRAC considers that bupropion may unmask Brugada syndrome. Physicians need, therefore, be advised to be cautious in patients with a family history of cardiac arrest or sudden death. Patients should also be adequately informed on this issue by the PL. The PRAC concluded that the product information of products containing bupropion should be amended.

The CMDh agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the Marketing Authorisation(s)

On the basis of the scientific conclusions for bupropion the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing bupropion is unchanged subject to the proposed changes to the product information.

The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing bupropion are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text **underlined and in bold**, deleted text ~~strike-through~~)

Summary of Product Characteristics

Section 4.4

A warning should be added as follows:

Brugada syndrome

Bupropion may unmask Brugada syndrome, a rare hereditary disease of the cardiac sodium channel with characteristic ECG changes (right bundle branch block and ST segment elevation in right precordial leads), which may lead to cardiac arrest or sudden death. Caution is advised in patients with Brugada syndrome or a family history of cardiac arrest or sudden death.

Package Leaflet

Section 2 – What you need to know before you take [tradenam]

[...]

Warnings and precautions

Talk to your doctor or pharmacist before taking [tradenam]:

Brugada syndrome

- if you have a condition called Brugada syndrome (a rare hereditary syndrome that affects the heart rhythm) or if cardiac arrest or sudden death occurred in your family.

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	Sep 2022 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	30 October 2022
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	29 December 2022